NOBIVAC® CANINE 1-DAPPV
A modified live vaccine for the immunisation of healthy dogs against canine distemper, adenovirus type 2, infectious canine hepatitis, parainfluenza and parvovirus.
NOBIVAC® CANINE 1-DAPPV
FOR ANIMAL USE ONLY
Reg. No. G3892 (Act 36/1947)
Namibia Reg. No. V04/24.1/903 [NS2]
This vaccine may only be used by or under the supervision of persons registered in terms of or authorised in terms of section 23 (1) (c) of the Veterinary and Para-veterinary Professions Act, 1982 (Act No. 19 of 1982).
INDICATIONS
A modified live vaccine for the immunisation of healthy dogs against canine distemper, adenovirus type 2, infectious canine hepatitis, parainfluenza and parvovirus.
COMPOSITION
Modified live vaccine containing canine distemper virus, canine adenovirus type 2, canine parainfluenza virus and canine parvovirus type 2b strain.
Maximum moisture content at release: ≤ 5,5 %.
Contains gentamicin as a preservative.
STORAGE INSTRUCTIONS
- Store between 2 °C – 7 °C in a refrigerator.
- Do not freeze.
- Protect from light.
- Use entire contents immediately after reconstitution.
WARNINGS
- DO NOT VACCINATE PREGNANT BITCHES.
- Vaccinate only healthy, non-parasitised dogs.
- Do not mix Nobivac® Canine 1-DAPPv with any other vaccine or medication.
- Do not over- or underdose the vaccine.
- Do not inject intravenously.
- KEEP OUT OF REACH OF CHILDREN, UNINFORMED PERSONS AND ANIMALS.
- Although this vaccine has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.
PRECAUTIONS
- Observe aseptic precautions. Ensure that all vaccination equipment (containers, syringes and needles) is clean and sterile prior to and during use. Use sterile equipment when administering the vaccine.
- Do not use disinfectants or antiseptics to sterilise any equipment.
- Anaphylactic or hypersensitivity reactions may occur.
- Adhere to the vaccination programme to obtain optimum results.
- Do not eat, drink or smoke whilst handling the product.
- Destroy any unused vaccine and dispose of all the empty vaccine containers and disposable equipment after use in accordance with National Environmental Management: Waste Act, 2008 (Act No. 59 of 2008).
- Do not contaminate rivers, dams or any water sources with containers or waste.
Antidote: Adrenaline, corticosteroids and antihistamines may all be indicated depending on the nature and severity of the reaction.
DIRECTIONS FOR USE – USE ONLY AS DIRECTED
- Transfer the contents of the sterile diluent vial to the Nobivac® Canine 1-DAPPv vial aseptically.
- Gently mix until well dissolved.
- Inject subcutaneously or intramuscularly at 6 weeks of age or older.
- Repeat dosage at 2 to 4 week intervals until the dog is 12 weeks old.
- A minimum of two 1 mℓ doses are required for primary immunisation.
- Although duration of immunity is at least 4 years for distemper, adenovirus (CAV1 and CAV2) and parvovirus.
- Annual revaccination with one dose is recommended for the individual risk profile or immune status.
PRESENTATION
Type I glass vials, containing off-white freeze-dried vaccine, closed with a rubber stopper and sealed with an aluminum cap. Nobivac® 1-DAPPv vials are accompanied by sterile diluent vials in a polyvinyl chloride (PVC) tray, which contains 25 vials of 1 dose (1 mℓ) or 5 vials of 10 doses (10 mℓ). Carton must be sold as a unit. Do not break seal or open before sale.
REGISTRATION HOLDER
Intervet South Africa (Pty) Ltd.
20 Spartan Road, Spartan
RSA, 1619
Tel. +27 (0) 11 923 9300
DATE OF PUBLICATION OF THIS PACKAGE INSERT
14 December 2010